JP2014028814A - Ageの脱糖化 - Google Patents
Ageの脱糖化 Download PDFInfo
- Publication number
- JP2014028814A JP2014028814A JP2013169506A JP2013169506A JP2014028814A JP 2014028814 A JP2014028814 A JP 2014028814A JP 2013169506 A JP2013169506 A JP 2013169506A JP 2013169506 A JP2013169506 A JP 2013169506A JP 2014028814 A JP2014028814 A JP 2014028814A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- age
- skin
- substance
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000006325 deglycation Effects 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 51
- 239000000126 substance Substances 0.000 claims abstract description 28
- 239000004480 active ingredient Substances 0.000 claims abstract description 23
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 230000032683 aging Effects 0.000 claims abstract description 9
- 230000009467 reduction Effects 0.000 claims abstract description 7
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 claims description 32
- 239000013543 active substance Substances 0.000 claims description 29
- 235000000346 sugar Nutrition 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 20
- 230000036252 glycation Effects 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 239000000284 extract Substances 0.000 claims description 16
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 claims description 14
- 239000002537 cosmetic Substances 0.000 claims description 14
- 230000022811 deglycosylation Effects 0.000 claims description 14
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 claims description 12
- 241000196324 Embryophyta Species 0.000 claims description 11
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 claims description 10
- 239000000419 plant extract Substances 0.000 claims description 10
- 102000008186 Collagen Human genes 0.000 claims description 8
- 108010035532 Collagen Proteins 0.000 claims description 8
- PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 claims description 8
- 229920001436 collagen Polymers 0.000 claims description 8
- 238000011534 incubation Methods 0.000 claims description 8
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 claims description 8
- 235000007297 Gaultheria procumbens Nutrition 0.000 claims description 7
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 229960001553 phloroglucinol Drugs 0.000 claims description 7
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 6
- PFTAWBLQPZVEMU-HIFRSBDPSA-N (-)-catechin Chemical compound C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-HIFRSBDPSA-N 0.000 claims description 6
- FCSPXCQJNMMNMO-UHFFFAOYSA-N 7-hydroxy-4,6-dimethyl-3h-2-benzofuran-1-one Chemical compound CC1=CC(C)=C(O)C2=C1COC2=O FCSPXCQJNMMNMO-UHFFFAOYSA-N 0.000 claims description 6
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 6
- 235000005487 catechin Nutrition 0.000 claims description 6
- 229950001002 cianidanol Drugs 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- XAWPKHNOFIWWNZ-UHFFFAOYSA-N 1h-indol-6-ol Chemical compound OC1=CC=C2C=CNC2=C1 XAWPKHNOFIWWNZ-UHFFFAOYSA-N 0.000 claims description 5
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 claims description 5
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 claims description 5
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 claims description 5
- OGMGXKJQIOUTTB-RGMNGODLSA-N hydron;(1s)-1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol;bromide Chemical compound Br.OC1=C(O)C=C2[C@H](C)NCCC2=C1 OGMGXKJQIOUTTB-RGMNGODLSA-N 0.000 claims description 5
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 claims description 5
- 229960003951 masoprocol Drugs 0.000 claims description 5
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 claims description 5
- 229960001697 physostigmine Drugs 0.000 claims description 5
- IBRKLUSXDYATLG-UHFFFAOYSA-N salsolinol hydrobromide Natural products OC1=C(O)C=C2C(C)NCCC2=C1 IBRKLUSXDYATLG-UHFFFAOYSA-N 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- RLNWRDKVJSXXPP-UHFFFAOYSA-N tert-butyl 2-[(2-bromoanilino)methyl]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1CNC1=CC=CC=C1Br RLNWRDKVJSXXPP-UHFFFAOYSA-N 0.000 claims description 5
- VHBSECWYEFJRNV-UHFFFAOYSA-N 2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O.OC(=O)C1=CC=CC=C1O VHBSECWYEFJRNV-UHFFFAOYSA-N 0.000 claims description 4
- 241000167854 Bourreria succulenta Species 0.000 claims description 4
- LXCFLOSCXGXJGS-UHFFFAOYSA-N C(C=CC1=CC(OC)=C(O)C(OC)=C1)(=O)O.COC=1C=C(C=CC(=O)O)C=C(C1O)OC Chemical compound C(C=CC1=CC(OC)=C(O)C(OC)=C1)(=O)O.COC=1C=C(C=CC(=O)O)C=C(C1O)OC LXCFLOSCXGXJGS-UHFFFAOYSA-N 0.000 claims description 4
- 244000097582 Cecropia peltata Species 0.000 claims description 4
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 4
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 4
- 241000624130 Phoradendron piperoides Species 0.000 claims description 4
- FNNLUWYUFVEPNA-UHFFFAOYSA-N ac1lfk42 Chemical compound C1=CC=C2C(=O)N3C4=NC5=CC=CC=C5C(=O)N4C=C(C)C3=NC2=C1 FNNLUWYUFVEPNA-UHFFFAOYSA-N 0.000 claims description 4
- 235000019693 cherries Nutrition 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 241001299678 Cecropia Species 0.000 claims description 3
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 3
- 241000018646 Pinus brutia Species 0.000 claims description 3
- 235000011613 Pinus brutia Nutrition 0.000 claims description 3
- 239000002532 enzyme inhibitor Substances 0.000 claims description 3
- 229960004705 kojic acid Drugs 0.000 claims description 3
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 239000013589 supplement Substances 0.000 claims description 3
- XZHWAGZSWOAEPI-UHFFFAOYSA-N C(C=CC1=CC(O)=C(O)C=C1)(=O)O.OC=1C=C(C=CC(=O)O)C=CC1O Chemical compound C(C=CC1=CC(O)=C(O)C=C1)(=O)O.OC=1C=C(C=CC(=O)O)C=CC1O XZHWAGZSWOAEPI-UHFFFAOYSA-N 0.000 claims description 2
- 235000005273 Canna coccinea Nutrition 0.000 claims description 2
- 244000292211 Canna coccinea Species 0.000 claims description 2
- 241000736246 Pyrola Species 0.000 claims 3
- 241001491790 Bupalus piniaria Species 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 abstract description 6
- 210000000056 organ Anatomy 0.000 abstract description 5
- 235000018102 proteins Nutrition 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 239000000047 product Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 150000008163 sugars Chemical class 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 108091005996 glycated proteins Proteins 0.000 description 5
- -1 pentosidine Chemical compound 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 240000001238 Gaultheria procumbens Species 0.000 description 4
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- 240000003444 Paullinia cupana Species 0.000 description 3
- 235000000556 Paullinia cupana Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002262 Schiff base Substances 0.000 description 3
- 150000004753 Schiff bases Chemical class 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 2
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 238000003691 Amadori rearrangement reaction Methods 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 241001354371 Cecropia obtusa Species 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241001362421 Epimedium brevicornu Species 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 235000008981 Smilax officinalis Nutrition 0.000 description 2
- 240000002493 Smilax officinalis Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229940036350 bisabolol Drugs 0.000 description 2
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 235000013681 dietary sucrose Nutrition 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 229960005150 glycerol Drugs 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 229940119170 jojoba wax Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002803 maceration Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- SBZWTSHAFILOTE-SOUVJXGZSA-N (2R,3S,4S)-leucocyanidin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3[C@H](O)[C@@H]2O)=CC=C(O)C(O)=C1 SBZWTSHAFILOTE-SOUVJXGZSA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- SUHQNCLNRUAGOO-KQCZLNONSA-N (4s,5r,6r,7s,8r)-4,6,7,8,9-pentahydroxy-5-[(2-hydroxyacetyl)amino]-2-oxononanoic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](NC(=O)CO)[C@@H](O)CC(=O)C(O)=O SUHQNCLNRUAGOO-KQCZLNONSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- JHRHFFULXFLTPE-UHFFFAOYSA-N 1-propan-2-yloxyhexadecan-2-ol Chemical compound CCCCCCCCCCCCCCC(O)COC(C)C JHRHFFULXFLTPE-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- QNESDXMHQYMNGD-UHFFFAOYSA-N 2,3-bis(3,5,5-trimethylhexanoyloxy)propyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CC(=O)OCC(OC(=O)CC(C)CC(C)(C)C)COC(=O)CC(C)CC(C)(C)C QNESDXMHQYMNGD-UHFFFAOYSA-N 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- BJRXGOFKVBOFCO-UHFFFAOYSA-N 2-hydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(C)O BJRXGOFKVBOFCO-UHFFFAOYSA-N 0.000 description 1
- SGRCVQDBWHCTIS-UHFFFAOYSA-N 2-nonanoyloxypropyl nonanoate Chemical compound CCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCC SGRCVQDBWHCTIS-UHFFFAOYSA-N 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- NJLKZOZYTRRDBO-UHFFFAOYSA-N 3-iodopropyl n-butylcarbamate Chemical compound CCCCNC(=O)OCCCI NJLKZOZYTRRDBO-UHFFFAOYSA-N 0.000 description 1
- VZRRCQOUNSHSGB-UHFFFAOYSA-N 4-hydroxy-4,6,6-trimethylbicyclo[3.1.1]heptan-3-one Chemical compound C1C2C(C)(C)C1CC(=O)C2(O)C VZRRCQOUNSHSGB-UHFFFAOYSA-N 0.000 description 1
- PWWCDTYUYPOAIU-DHZHZOJOSA-N 4-hydroxychalcone Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=CC=C1 PWWCDTYUYPOAIU-DHZHZOJOSA-N 0.000 description 1
- JMHFFDIMOUKDCZ-NTXHZHDSSA-N 61214-51-5 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 JMHFFDIMOUKDCZ-NTXHZHDSSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 240000000662 Anethum graveolens Species 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102400000748 Beta-endorphin Human genes 0.000 description 1
- 101800005049 Beta-endorphin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 235000019120 Chimaphila umbellata Nutrition 0.000 description 1
- 244000295519 Chimaphila umbellata Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 241001257574 Davilla rugosa Species 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- XTJFFFGAUHQWII-UHFFFAOYSA-N Dibutyl adipate Chemical compound CCCCOC(=O)CCCCC(=O)OCCCC XTJFFFGAUHQWII-UHFFFAOYSA-N 0.000 description 1
- 235000005903 Dioscorea Nutrition 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- 235000000504 Dioscorea villosa Nutrition 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 235000014066 European mistletoe Nutrition 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000208690 Hamamelis Species 0.000 description 1
- 244000153234 Hibiscus abelmoschus Species 0.000 description 1
- 235000010616 Hibiscus abelmoschus Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000003918 Hyaluronan Synthases Human genes 0.000 description 1
- 108090000320 Hyaluronan Synthases Proteins 0.000 description 1
- 101710128038 Hyaluronan synthase Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000789133 Maprounea Species 0.000 description 1
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 1
- 101710200814 Melanotropin alpha Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000016357 Mirtillo rosso Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 101710096328 Phospholipase A2 Proteins 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 235000008124 Picea excelsa Nutrition 0.000 description 1
- 244000003162 Pinus excelsa Species 0.000 description 1
- 235000008596 Pinus excelsa Nutrition 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 244000152640 Rhipsalis cassutha Species 0.000 description 1
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
- 241000698291 Rugosa Species 0.000 description 1
- 240000004284 Rumex crispus Species 0.000 description 1
- 235000021501 Rumex crispus Nutrition 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 244000151637 Sambucus canadensis Species 0.000 description 1
- 235000018735 Sambucus canadensis Nutrition 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000019032 Stachytarpheta jamaicensis Nutrition 0.000 description 1
- 240000008104 Stachytarpheta jamaicensis Species 0.000 description 1
- 241000009298 Trigla lyra Species 0.000 description 1
- 235000017606 Vaccinium vitis idaea Nutrition 0.000 description 1
- 244000077923 Vaccinium vitis idaea Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 description 1
- ZGBSOTLWHZQNLH-UHFFFAOYSA-N [Mg].S(O)(O)(=O)=O Chemical compound [Mg].S(O)(O)(=O)=O ZGBSOTLWHZQNLH-UHFFFAOYSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 229940093740 amino acid and derivative Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- LSOTZYUVGZKSHR-UHFFFAOYSA-N anthracene-1,4-dione Chemical compound C1=CC=C2C=C3C(=O)C=CC(=O)C3=CC2=C1 LSOTZYUVGZKSHR-UHFFFAOYSA-N 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- UIFJOXOHICDFDO-UHFFFAOYSA-N benzene-1,3,5-triol Chemical compound OC1=CC(O)=CC(O)=C1.OC1=CC(O)=CC(O)=C1 UIFJOXOHICDFDO-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 235000007123 blue elder Nutrition 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 229940071160 cocoate Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000008408 compound extracted from plant Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940100539 dibutyl adipate Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 229960001826 dimethylphthalate Drugs 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000007124 elderberry Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 229940080322 erythrosine sodium Drugs 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 235000019866 hydrogenated palm kernel oil Nutrition 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 229940060384 isostearyl isostearate Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 239000006224 matting agent Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000012184 mineral wax Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- DLIKSSGEMUFQOK-SFTVRKLSSA-N naringenin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C(C(=O)C[C@H](O2)C=3C=CC(O)=CC=3)C2=C1 DLIKSSGEMUFQOK-SFTVRKLSSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000005474 octanoate group Chemical group 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 229940031709 peg-30-dipolyhydroxystearate Drugs 0.000 description 1
- AYEKKSTZQYEZPU-RYUDHWBXSA-N pentosidine Chemical compound OC(=O)[C@@H](N)CCCCN1C=CC=C2N=C(NCCC[C@H](N)C(O)=O)N=C12 AYEKKSTZQYEZPU-RYUDHWBXSA-N 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000059 polyethylene glycol stearate Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920005903 polyol mixture Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000004844 protein turnover Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- RXVLWCCRHSJBJV-UHFFFAOYSA-N prunin Natural products OCC1OC(O)C(Oc2cc(O)c3C(=O)CC(Oc3c2)c4ccc(O)cc4)C(O)C1O RXVLWCCRHSJBJV-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229940080340 sodium dihydroxycetyl phosphate Drugs 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- VDHLWCWZVFZQLZ-UHFFFAOYSA-M sodium;bis(2-hydroxyhexadecyl) phosphate Chemical compound [Na+].CCCCCCCCCCCCCCC(O)COP([O-])(=O)OCC(O)CCCCCCCCCCCCCC VDHLWCWZVFZQLZ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940098760 steareth-2 Drugs 0.000 description 1
- 229940100458 steareth-21 Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940116962 triisononanoin Drugs 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/415—Aminophenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
- A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cell Biology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Abstract
【解決手段】組織中のAGEの存在を制限するための組成物の調製のための、AGEの脱糖化を促す少なくとも1つの物質を活性成分として使用する。
【選択図】なし
Description
1:還元糖(グルコース、リボースまたはフルクトース)の、あるいはアルデヒドの、タンパク質のアミノ酸残基との、主にリシンおよびN末端アミン画分との結合に起因するシッフ塩基の形成。
2:シッフ塩基の異性化に起因するアマドリ転位として知られている分子転位。これらのアマドリ生成物の形成速度は、糖濃度に比例する。
3:糖化最終産物またはメイラード生成物の、転位、水素移動および極反応性中間体の形成による、ゆっくりとした不可逆的蓄積。この反応は、メイラード生成物という表現によってよりよく知られているAGEの形成をもたらす。これらの化合物の形成速度は、媒質の糖濃度とは無関係であるが、しかし高血糖の持続期間、ならびにタンパク質ターンオーバー速度に左右される。
・awati(マプロウネア・グヤネンシス(Maprounea guyanensis))、および好ましくはその葉;
・ジャマイカ・クマツヅラ(スタキタルフェタ・ジャマイセンシス(Stachytarpheta jamaicensis));
・セクロピア(セクロピア・オブツサ(Cecropia obtusa))、および好ましくはその葉および/または芽;ならびに
・ウインターグリーン(キマフィラ・ウンベラタ(Chimaphila umbellata))
からなる群から選択される植物抽出物である。
・3,5−ジメトキシ−4−ヒドロキシ桂皮酸(シナピン酸);
・トランス−3,3’,4’,5,7−ペンタヒドロキシフラバン(カテキン);
・オキシインドール;
・3,4−ジヒドロキシフェニル酢酸(DOPAC);
・1,3,5−トリヒドロキシベンゼン(フロログルシノール);
およびその混合物、ならびにそれらを含有する植物抽出物
からなる群から選択される特性決定された分子である。
・awati(マプロウネア・グヤネンシス)、および好ましくはその葉;
・ジャマイカ・クマツヅラ(スタキタルフェタ・ジャマイセンシス);
・セクロピア(セクロピア・オブツサ)、および好ましくはその葉および/または芽;ならびに
・ウインターグリーン(キマフィラ・ウンベラタ)
からなる群から選択される植物抽出物である。
・3,5−ジメトキシ−4−ヒドロキシ桂皮酸(シナピン酸);
・トランス−3,3’,4’,5,7−ペンタヒドロキシフラバン(カテキン);
・オキシインドール;
・3,4−ジヒドロキシフェニル酢酸(DOPAC);
・1,3,5−トリヒドロキシベンゼン(フロログルシノール);
からなる群から選択される特性決定された分子である。
(a)AGEを生成するステップ;
(b)AGEの脱糖化に関連したその活性に関してスクリーニングすつ対象の物質とAGEを接触させるステップ;および
(c)AGEの脱糖化を促す少なくとも1つの活性成分を選択するステップ
を含む方法にも関する。
・抗老化作用を有する細胞増殖および/または分化を刺激する活性物質、特に以下の分子:NGF、α−MSH、β−エンドルフィンまたはその誘導体、特に特許出願FR2857874に記載されているもの;
・繊維芽細胞増殖因子(FGF)特にFGF2を保護する活性物質、特にGB244036として公開された本出願人の名で特許出願に記載されているもの、特にアンブレット・シード(ヒビスクス・アベルモスクス(Hibiscus abelmoschus))の抽出物;
・繊維芽細胞の活性および/または増殖を刺激する活性物質、特に、発酵大豆ペプチド、有利にはアンブレット・シードの抽出物と組合せて、フィトカイン(商標)の名称で本出願人により販売されているもの;
・ヒアルロン酸シンターゼ、特にHAS2を刺激する活性物質、特に特許FR2893252に記載されたもの;
・リシルオキシダーゼ、特にLOXの活性および/または合成を刺激する活性物質、特に特許出願FR2855968に記載されているもの、特にディル抽出物;ならびに
・抗炎症特性を有する活性物質、例えばPLA2を抑制するもの、特に特許FR2847267に記載されたものなどのクズの根の抽出物(Inhipase(登録商標))。
メイラード反応の逆転
1.AGEの調製:
タンパク質および還元糖を含有する溶液の調製を、下準備なしで、以下のように実行した:1.5μM〜1.5M、好ましくは15μM〜500μMの濃度のウシ血清アルブミン(BSA)の溶液を、0.1M〜10M、好ましくは0.5M〜5Mの濃度の還元糖、例えばグルコース、フルクトースなどの溶液とともに、好ましくはグルコースとともにインキュベートした。ウシ血清アルブミンの溶液は、ヒトコラーゲンに置き換えることができる。
1で調製したAGEを含有する溶液を、そのAGE脱糖化活性に関して試験する対象の化合物の存在下で、または非存在下で(陰性対照)、40〜60℃、好ましくは約50℃の温度で、1〜5週間、好ましくは3週間、インキュベートした。総組成物の0.001〜10重量%、好ましくは0.01〜5重量%、特に1重量%の濃度で、化合物を試験した。用いた陽性対照は、15μM〜150mMの濃度の、好ましくは1.5〜15mMの濃度のアミノグアニジンであった。蛍光を測定することにより、AGEの抑制の測定を実施した(励起波長350〜375nm、好ましくは355nm;発光波長420〜450nm、好ましくは430nm)。100%(最大蛍光)に設定されたAGEの蛍光を、AGE+試験した活性剤の蛍光と比較することにより、メイラード反応の逆転を算定した。
特性決定された分子によるAGEの脱糖化
実施例1(段落1)に記載した方法に従って、タンパク質/還元糖溶液の調製を実施した。実施例1(段落2)に記載したように、例えば水またはDMSO中の1×10−7〜1×10−1重量%、好ましくは1×10−5〜1×10−1重量%、特に1×10−1重量%の濃度で、分子を試験した。
植物抽出物によるAGEの脱糖化
実施例1(段落1)に記載した方法に従って、タンパク質/還元糖の溶液の調製を実施した。
ヒトコラーゲンの脱糖化における本発明の物質の活性
BSAの代わりにヒトコラーゲンを用いて、実施例1(段落1)に記載した方法に従って、タンパク質/還元糖の溶液の調製を実行した。
形成外科手術から得たヒト生検から、ヒトコラーゲンを抽出した。溶液の形態で得られたコラーゲンを、還元糖、例えばグルコース、フルクトースまたはリボースとともに、好ましくはリボースとともにインキュベートした。インキュベーション濃度は、前記実施例に記載したものと同一とした。
「植物抽出物」型の、および「特性決定された分子」型の潜在的活性成分を、実施例2および3に記載したものと同一条件下で用いた。
記載した条件下で、用いた15mMアミノグアニジンのものと少なくとも同等の様式で、AGEの脱糖化を促す分子は、実施例2および3に記載したものと同一であった。
局所的に適用され得る老化防止組成物
以下の実施例において、「本発明の生成物」は、本発明の活性物質、特に実施例2または3に従って得られたものを表す。
Claims (10)
- ヒト皮膚組織中のAGEの存在を制限するための組成物の調製のための、AGEに関するメイラード反応の逆転を促す少なくとも1つの物質の、局所適用による活性成分としての使用。
- AGEの脱糖化を促すための組成物を調製するための請求項1に記載の使用であって、前記活性物質が、以下:3,5−ジメトキシ−4−ヒドロキシ桂皮酸(シナピン酸)、トランス−3,3’,4’,5,7−ペンタヒドロキシフラバン(カテキン)、オキシインドール、3,4−ジヒドロキシフェニル酢酸(DOPAC)、1,3,5−トリヒドロキシベンゼン(フロログルシノール)、4−アミノフェノール、2−ヒドロキシ安息香酸(サリチル酸)、6−ヒドロキシ−2,5,7,8−テトラメチルクロマン−2−カルボン酸(トロロックス)、ノルジヒドログアイアレチン酸、6−メチル−5,7a,13,13b−テトラアザペンタフェン−8,14−ジオン、6−ヒドロキシインドール、サルソリノール臭化水素酸塩、7−ヒドロキシ−4,6−ジメチルフタリド、3,4−ジヒドロキシ桂皮酸(カフェイン酸)、フィゾスチグミン、2−ヒドロキシメチル−5−ヒドロキシ−γ−ピロン(コウジ酸)、以下の:awati、ジャマイカ・クマツヅラ、セクロピア、ウインターグリーン、piper mistletoe、サクラ、カッシアおよびダンドク(Indian shot)からなる群から選択される植物の少なくとも1つの抽出物、ならびにその任意の混合物からなる群から選択される、上記使用。
- 前記組成物が局所的に適用され得る化粧用組成物である、請求項1または請求項2に記載の使用。
- 前記組成物が、皮膚組織中のAGEの脱糖化を促すことにより、組織の柔軟性および/または可塑性および/または弾力性および/または機能性の低減を予防しかつ/またはこれに対抗する、ならびに/あるいは組織の老化を予防しかつ/またはこれに対抗することが意図される、請求項1〜3のいずれか1項に記載の使用。
- 前記物質が、総組成物のうち、好ましくは植物抽出物に関して0.001〜10重量%の濃度、および特性決定された分子に関して10−7〜1重量%の濃度で用いられる、請求項1〜4のいずれか1項に記載の使用。
- AGEの脱糖化を促す活性成分のスクリーニング方法であって、以下のステップ:
(a)AGEを生成するステップ;
(b)AGEの脱糖化に関連したその活性に関してスクリーニングする対象の物質とAGEを接触させるステップ;および
(c)AGEの脱糖化を促す少なくとも1つの活性成分を選択するステップ
を含む方法。 - ステップ(a)が、AGEの形成を可能にする条件下での、糖の存在下での、皮膚からのまたは血管壁からの少なくとも1種類のタンパク質、例えばヒトコラーゲンのインキュベーションを含む、請求項6に記載のスクリーニング方法。
- ステップ(b)が、40〜60℃、好ましくは約50℃の温度でスクリーニング対象の少なくとも1つの物質の存在下でのAGEのインキュベーションを含む、請求項6に記載のスクリーニング方法。
- 皮膚中のAGEの脱糖化を促すことにより、皮膚の柔軟性および/または可塑性および/または弾力性および/または機能性の低減を予防しかつ/またはこれに対抗する、ならびに/あるいは皮膚の老化を予防しかつ/またはこれに対抗することが意図される、局所的にまたは食品(栄養)補助剤として適用され得る化粧用組成物であって、任意に、糖化を抑制する化合物、または皮膚タンパク質の保護を促す物質、または酵素阻害剤、または糖化反応に参加するために利用可能な糖の量を低減する物質との混合物として、好ましくはオキシインドール、3,4−ジヒドロキシフェニル酢酸(DOPAC)、1,3,5−トリヒドロキシベンゼン(フロログルシノール)、4−アミノフェノール、2−ヒドロキシ安息香酸(サリチル酸)、6−ヒドロキシ−2,5,7,8−テトラメチルクロマン−2−カルボン酸(トロロックス)、ノルジヒドログアイアレチン酸、6−メチル−5,7a,13,13b−テトラアザペンタフェン−8,14−ジオン、6−ヒドロキシインドール、サルソリノール臭化水素酸塩、7−ヒドロキシ−4,6−ジメチルフタリド、フィゾスチグミン、以下:awati、ジャマイカ・クマツヅラ、セクロピア、ウインターグリーン、piper mistletoe、サクラ、カッシアおよびダンドクからなる群から選択される植物の少なくとも1つの抽出物;ならびにその任意の混合物からなる群から選択されるヒト皮膚中のAGEに関するメイラード反応の逆転を促す物質を活性成分として含む、上記組成物。
- 任意に、糖化を抑制する化合物、または皮膚タンパク質の保護を促す物質、または酵素阻害剤、または糖化反応に参加するために利用可能な糖の量を低減する物質との混合物として、好ましくはオキシインドール、3,4−ジヒドロキシフェニル酢酸(DOPAC)、1,3,5−トリヒドロキシベンゼン(フロログルシノール)、4−アミノフェノール、2−ヒドロキシ安息香酸(サリチル酸)、6−ヒドロキシ−2,5,7,8−テトラメチルクロマン−2−カルボン酸(トロロックス)、ノルジヒドログアイアレチン酸、6−メチル−5,7a,13,13b−テトラアザペンタフェン−8,14−ジオン、6−ヒドロキシインドール、サルソリノール臭化水素酸塩、7−ヒドロキシ−4,6−ジメチルフタリド、フィゾスチグミン、以下:awati、ジャマイカ・クマツヅラ、セクロピア、ウインターグリーン、piper mistletoe、サクラ、カッシアおよびダンドクからなる群から選択される植物の少なくとも1つの抽出物;ならびにその任意の混合物からなる群から選択される皮膚中のAGEに関するメイラード反応の逆転を促す物質を活性成分として含む、皮膚の柔軟性および/または可塑性および/または弾力性および/または機能性の低減を予防しかつ/またはこれに対抗することが特に意図される医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0756350 | 2007-07-09 | ||
FR0756350A FR2918570B1 (fr) | 2007-07-09 | 2007-07-09 | DIGLYCATION DES AGEs. |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010515508A Division JP2010533143A (ja) | 2007-07-09 | 2008-07-09 | Ageの脱糖化 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2014028814A true JP2014028814A (ja) | 2014-02-13 |
Family
ID=39262794
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010515508A Pending JP2010533143A (ja) | 2007-07-09 | 2008-07-09 | Ageの脱糖化 |
JP2013169506A Pending JP2014028814A (ja) | 2007-07-09 | 2013-08-19 | Ageの脱糖化 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010515508A Pending JP2010533143A (ja) | 2007-07-09 | 2008-07-09 | Ageの脱糖化 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20100203175A1 (ja) |
EP (1) | EP2170358A2 (ja) |
JP (2) | JP2010533143A (ja) |
KR (1) | KR20100047253A (ja) |
CN (2) | CN103816095A (ja) |
BR (1) | BRPI0813925A2 (ja) |
FR (2) | FR2918570B1 (ja) |
WO (1) | WO2009007412A2 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2928548B1 (fr) * | 2008-03-14 | 2015-07-03 | Basf Beauty Care Solutions F | Substances augmentant le seuil d'activation des cellules immunes |
JP2010077123A (ja) * | 2008-08-29 | 2010-04-08 | Hayashikane Sangyo Kk | メイラード反応阻害剤 |
FR2951085B1 (fr) * | 2009-10-09 | 2012-05-18 | Inst Substances Vegetales | Utilisation de composes phenoliques pour la deglycation des proteines |
FR2954702B1 (fr) | 2009-12-31 | 2013-07-05 | Basf Beauty Care Solutions F | Agent stimulant l'expression de loxl |
US20130196937A1 (en) * | 2010-02-10 | 2013-08-01 | Oryza Oil & Fat Chemical Co., Ltd. | Age production inhibitor |
JP6012138B2 (ja) * | 2010-10-04 | 2016-10-25 | 小林製薬株式会社 | 抗糖化剤 |
JP5855492B2 (ja) * | 2012-02-27 | 2016-02-09 | 三省製薬株式会社 | AGEs産生抑制剤 |
JP6054700B2 (ja) * | 2012-10-10 | 2016-12-27 | 株式会社ノエビア | 脱糖化剤及び皮膚外用剤 |
JP2015096488A (ja) * | 2013-10-10 | 2015-05-21 | 康二 嘉島 | 終末糖化物質生成抑制方法 |
CN105832724B (zh) * | 2015-10-16 | 2018-07-03 | 北京冠瑞金生物科技有限公司 | 吲哚醇在制备抗抑郁症药物中的用途 |
JP2017088538A (ja) * | 2015-11-10 | 2017-05-25 | 日本メナード化粧品株式会社 | フィラグリン産生促進剤 |
KR102605628B1 (ko) * | 2015-12-29 | 2023-11-22 | 주식회사 엘지생활건강 | 하스타토사이드를 포함하는 피부상태 개선용 조성물 |
EP3641725A1 (en) * | 2017-06-23 | 2020-04-29 | The Procter and Gamble Company | Composition and method for improving the appearance of skin |
JP2019214546A (ja) * | 2018-06-11 | 2019-12-19 | 学校法人福岡大学 | 終末糖化産物生成抑制剤及び医薬組成物 |
CN112437657A (zh) | 2018-07-03 | 2021-03-02 | 宝洁公司 | 处理皮肤状况的方法 |
CN109468370A (zh) * | 2018-11-09 | 2019-03-15 | 广州益养生物科技有限公司 | 一种快速检测遗传性皮肤糖基化能力基因的方法 |
CN110684212A (zh) * | 2019-10-31 | 2020-01-14 | 东南大学 | 一种仿贻贝的水下高粘性水凝胶的制备方法 |
US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
EP4157206A1 (en) | 2020-06-01 | 2023-04-05 | The Procter & Gamble Company | Method of improving penetration of a vitamin b3 compound into skin |
CN112111020B (zh) * | 2020-10-26 | 2022-07-19 | 无锡善元健康管理有限公司 | 桦树茸中抗糖成分的提取纯化及抗糖丸的制备方法 |
CN112370370B (zh) * | 2020-11-19 | 2022-07-26 | 苏州禾研生物技术有限公司 | 一种氧糖双抗的组合物及其应用和氧糖双抗的产品 |
CN113876668B (zh) * | 2021-11-16 | 2023-11-03 | 上海青颜博识生物技术有限公司 | 一种抗糖化植物来源组合物及其制备方法和在美容产品中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000256259A (ja) * | 1999-03-11 | 2000-09-19 | Nippon Zoki Pharmaceut Co Ltd | メイラード反応阻害剤 |
JP2005179341A (ja) * | 2003-12-17 | 2005-07-07 | Avon Products Inc | チアゾール誘導体 |
JP2007119373A (ja) * | 2005-10-26 | 2007-05-17 | Arkray Inc | メイラード反応生成物分解剤およびそれを用いた飲食品 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4847267A (en) * | 1986-03-17 | 1989-07-11 | Charles Of The Ritz Group Ltd. | Skin treatment composition and method |
JP2552297B2 (ja) * | 1987-07-03 | 1996-11-06 | ポーラ化成工業株式会社 | 美肌化粧料 |
FR2653336B1 (fr) * | 1989-10-20 | 1994-04-08 | Oreal | Composition pharmaceutique et cosmetiques depigmentantes a base d'acide cafeique. |
ES2153366T3 (es) * | 1991-11-25 | 2001-03-01 | Richardson Vicks Inc | Uso de acido salicilico para regular la atrofia de la piel. |
US5888984A (en) * | 1994-05-12 | 1999-03-30 | Dermal Research Laboratories, Inc. | Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same |
JP3625501B2 (ja) * | 1994-10-06 | 2005-03-02 | 御木本製薬株式会社 | 細胞賦活用皮膚外用剤原料の製造方法及び細胞賦活用皮膚外用剤 |
JPH08133940A (ja) * | 1994-11-02 | 1996-05-28 | Pola Chem Ind Inc | 紫外線吸収剤及びこれを含有する化粧料 |
JPH0977655A (ja) * | 1995-09-14 | 1997-03-25 | Mikimoto Pharmaceut Co Ltd | 皮膚外用剤 |
FR2764190B1 (fr) * | 1997-06-06 | 1999-10-15 | Serobiologiques Lab Sa | Produit cosmetique comprenant des extraits de plantes notamment a action depigmentante, antiradicalaire et anti-vieillissement |
US6121300A (en) * | 1998-11-10 | 2000-09-19 | Wagle; Dilip R. | Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts |
FR2787324B1 (fr) * | 1998-12-21 | 2001-02-23 | Serobiologiques Lab Sa | Utilisation d'au moins un extrait d'une plante appartenant au genre cecropia et composition cosmetique ou dermopharmaceutique comportant un tel extrait |
EP1165064B1 (en) * | 1999-04-05 | 2004-02-25 | City of Hope | Novel inhibitors of formation of advanced glycation endproducts (age's) |
US6589944B1 (en) * | 1999-04-05 | 2003-07-08 | City Of Hope | Breakers of advanced glycation endproducts |
US6787566B2 (en) * | 1999-04-05 | 2004-09-07 | City Of Hope | Breakers of advanced glycation endproducts |
EP1145709A1 (de) * | 2000-04-14 | 2001-10-17 | Laboratoires Serobiologiques | Verwendung von Naturstoffen zur Herstellung von kosmetischen Zubereitungen |
FR2813195B1 (fr) * | 2000-08-29 | 2003-04-04 | Serobiologiques Lab Sa | Utilisation d'extraits de la plante cassia alata dans des produits de soin |
US20020127256A1 (en) * | 2001-03-01 | 2002-09-12 | Howard Murad | Compositions and methods for treating dermatological disorders |
DK1373263T3 (da) * | 2001-04-05 | 2005-03-07 | Torrent Pharmaceuticals Ltd | Heterocycliske forbindelser til aldringsrelaterede og diabetesbetingede vaskulære sygdomme |
EP1435930A2 (en) * | 2001-10-15 | 2004-07-14 | National Research Council Of Canada | Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications |
HUP0104831A2 (hu) * | 2001-10-19 | 2003-08-28 | Torrent Pharmaceuticals Ltd. | Készítmény és eljárás piridíniumszármazékok gyógyászati alkalmazására |
JP4247091B2 (ja) * | 2002-10-31 | 2009-04-02 | 池田食研株式会社 | 皮膚老化防止剤 |
KR20040038243A (ko) * | 2002-10-31 | 2004-05-08 | (주)마이코스메틱 | 생열귀나무 추출물을 함유하는 항산화 또는 항노화용 피부화장료 조성물 |
EP1437117A1 (de) * | 2002-12-19 | 2004-07-14 | Cognis France S.A. | Verwendung von Sinapinsäure und/oder Sinapinsäurederivaten |
CA2543404A1 (en) * | 2003-10-24 | 2005-05-06 | Meiji Seika Kaisha, Ltd. | Novel inhibitor of the formation of advanced glycation end product and aldose reductase inhibitor |
US20070098824A1 (en) * | 2005-10-27 | 2007-05-03 | Kgk Synergize Inc. | Canola extracts containing high levels of phenolic acids |
WO2008073684A1 (en) * | 2006-12-08 | 2008-06-19 | Lipo Chemicals Inc. | Composition for treating aging skin comprising a hydroxycinnamic acid such as p-coumaric acid |
-
2007
- 2007-07-09 FR FR0756350A patent/FR2918570B1/fr active Active
-
2008
- 2008-07-09 US US12/668,061 patent/US20100203175A1/en not_active Abandoned
- 2008-07-09 EP EP08786013A patent/EP2170358A2/fr not_active Withdrawn
- 2008-07-09 JP JP2010515508A patent/JP2010533143A/ja active Pending
- 2008-07-09 CN CN201410105347.2A patent/CN103816095A/zh active Pending
- 2008-07-09 WO PCT/EP2008/058955 patent/WO2009007412A2/fr active Application Filing
- 2008-07-09 KR KR1020107002758A patent/KR20100047253A/ko not_active Application Discontinuation
- 2008-07-09 BR BRPI0813925-3A2A patent/BRPI0813925A2/pt not_active IP Right Cessation
- 2008-07-09 CN CN200880101123A patent/CN101765432A/zh active Pending
-
2012
- 2012-07-20 FR FR1257027A patent/FR2975495B1/fr active Active
-
2013
- 2013-08-19 JP JP2013169506A patent/JP2014028814A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000256259A (ja) * | 1999-03-11 | 2000-09-19 | Nippon Zoki Pharmaceut Co Ltd | メイラード反応阻害剤 |
JP2005179341A (ja) * | 2003-12-17 | 2005-07-07 | Avon Products Inc | チアゾール誘導体 |
JP2007119373A (ja) * | 2005-10-26 | 2007-05-17 | Arkray Inc | メイラード反応生成物分解剤およびそれを用いた飲食品 |
Non-Patent Citations (2)
Title |
---|
PHARMAKEYTIKH PHARMAKEFTIKI(翻訳文付き), vol. 17, no. 4, JPN7015001053, 2004, pages 110 - 114, ISSN: 0003058020 * |
PHARMAKEYTIKH PHARMAKEFTIKI, vol. 17, no. 4, JPN6014039787, 2004, pages 110 - 114, ISSN: 0002901898 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009007412A2 (fr) | 2009-01-15 |
EP2170358A2 (fr) | 2010-04-07 |
KR20100047253A (ko) | 2010-05-07 |
FR2918570A1 (fr) | 2009-01-16 |
US20100203175A1 (en) | 2010-08-12 |
CN101765432A (zh) | 2010-06-30 |
FR2975495A1 (fr) | 2012-11-23 |
CN103816095A (zh) | 2014-05-28 |
BRPI0813925A2 (pt) | 2014-12-30 |
FR2975495B1 (fr) | 2017-06-09 |
JP2010533143A (ja) | 2010-10-21 |
FR2918570B1 (fr) | 2012-10-05 |
WO2009007412A3 (fr) | 2009-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014028814A (ja) | Ageの脱糖化 | |
US20100316743A1 (en) | INHIBITION OF THE FORMATION OF AGEs | |
KR101118139B1 (ko) | 디페닐메탄 유도체의 티로시나제 억제제로서의 용도 | |
EP3727603B1 (fr) | Extrait de fleurs de kapokier et compositions cosmetiques, pharmaceutiques ou dermatologiques le comprenant | |
JP2020518593A (ja) | 皮膚及び/又は粘膜の硬さを増大させるためのネフェリウム・ラッパセウム(Nephelium lappaceum)抽出物の使用 | |
FR2755367A1 (fr) | Utilisation d'un extrait de potentille erecta dans le domaine de la cosmetique et de la pharmacie, notamment de la dermatologie | |
JPH08259431A (ja) | メイラード反応阻害剤及びそれを含有する皮膚外用剤 | |
JP6055667B2 (ja) | コラーゲン産生促進剤 | |
WO2012014901A1 (ja) | カルボニル化抑制剤 | |
KR20160146246A (ko) | 항산화, 미백 및 주름개선 효과를 갖는 조성물 | |
KR101110301B1 (ko) | 쉬땅나무 추출물을 포함하는 피부미백용 화장료 조성물 | |
JP2012162487A (ja) | 美白剤、抗老化剤及び皮膚化粧料 | |
KR102052001B1 (ko) | 갈근초 및 아데노신을 포함하는 피부 노화 방지 또는 주름 개선용 화장료 조성물 | |
JP5412798B2 (ja) | 最終糖化産物の生成抑制剤、化粧料および飲食品 | |
EP4009940A1 (fr) | Nouvelle utilisation cosmétique d'un extrait d'epilobium angustifolium | |
JP2024088057A (ja) | 12型コラーゲン産生促進剤 | |
FR3138029A1 (fr) | Extrait anhydre de feuilles sans tige d’hippophae rhamnoides ou composition comprenant ledit extrait pour utilisation pour maintenir et/ou ameliorer la microcirculation cutanee et composition comprenant ledit extrait | |
JP2012126654A (ja) | ベオミセス酸含有抽出物の製造方法 | |
JP2011088856A (ja) | ツクシ抽出物を含有する化粧料 | |
KR20110075741A (ko) | 초임계 유체를 이용한 노루오줌 추출물을 함유하는 주름 개선용 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140924 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141218 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141224 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150115 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150421 |